Less than one year after selling an experimental medicine to Takeda for $4 billion, Nimbus Therapeutics is reloading with new funding meant to support its next wave of drug candidates, among them a prospective cancer therapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,